Edition:
United States

Almirall SA (ALM.MC)

ALM.MC on Madrid SE C.A.T.S.

14.37EUR
29 Jul 2016
Change (% chg)

€-0.12 (-0.83%)
Prev Close
€14.49
Open
€14.50
Day's High
€14.50
Day's Low
€14.31
Volume
143,124
Avg. Vol
224,567
52-wk High
€19.22
52-wk Low
€12.13

Select another date:

Wed, Jul 27 2016

BRIEF-Almirall signs license deal with Sun Pharma for psoriasis treatment

* Says enters into a license agreement with Sun Pharma Industries for tildrakizumab in Europe for psoriasis

BRIEF-Almirall reports H1 net profit up at 80.5 million euros

* H1 net profit 80.5 million euros ($88.53 million) versus 58.8 million euros year ago

BRIEF-Almirall H1 net profit 80.5 mln euros, up 37 pct year on year

* H1 net profit 80.5 million euros versus 58.8 million euros year ago

BRIEF-Almirall announces global licensing deal with Patagonia for congenital ichthyosis

* Announces global licensing deal with Patagonia Pharmaceuticals for congenital ichthyosis

Spain's Almirall eyes Valeant skin drugs to boost dermatology

MADRID Spanish drugmaker Almirall, which is building up its business in skin treatments, could be interested in acquiring dermatology assets from Canada's Valeant Pharmaceuticals, the head of the Barcelona-based company said on Monday. Valeant is looking at divesting various products as it tries to reduce its massive debt load, with new CEO Joe Papa open to selling a range of assets if the price is right.

BRIEF-Almirall's CFO, Daniel Martinez, steps down

* Says executive vice-president of finance (CFO), Daniel Martinez, steps down

BRIEF-Almirall signs US distribution deal with Sinclair Pharma

* Signs through its Dallas based company Thermigen, an exclusive US strategic marketing collaboration agreement for Silhouette Instalift (TM) with Sinclair Pharma Plc

BRIEF-Almirall and Bicosome to jointly develop topical drug delivery formulations

* Says enters into a collaboration and sublicense agreement with Bicosome to jointly develop topical drug delivery formulations

BRIEF-Almirall Q1 net profit down at 21.7 mln euros

* Q1 EBITDA 54.8 million euros ($62.5 million) versus 73.1 million euros year ago

BRIEF-Almirall SA sells unit and product license in Mexico for 50 mln euros

* Says to transfer 100 percent of its Mexico's unit to Grupo Grunenthal for 30 million euros ($33.3 million)

Select another date: